Company Profiles

driven by the PitchBook Platform

Anexon

Description

Developer of therapeutics for cardiovascular disease. The company is focused on developing an alternatively spliced variant of brain natriuretic peptide, ANX-042, for the treatment of patients with chronic heart failure and kidney dysfunction.

2006

Founded

PRIVATE

Status

1-10

Employees

2ndary - Private

Latest Deal Type

$8.5M

Total Amount Raised

1

Investors

Description

Developer of therapeutics for cardiovascular disease. The company is focused on developing an alternatively spliced variant of brain natriuretic peptide, ANX-042, for the treatment of patients with chronic heart failure and kidney dysfunction.

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Biotechnology

Other Industries

Pharmaceuticals
Drug Delivery

Primary Office

55 Cambridge Parkway Suite 102 Cambridge, MA 02142United States +1 (617) 252-4343
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Anexon's full profile, request a free trial.

    Anexon Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Anexon Investors (1)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Mayo Clinic VenturesCorporate Venture CapitalMinority000 0000000 0000
    Mayo Clinic Ventures Corporate Venture Capital

    Anexon Executive Team (1)

    NameTitleBoard
    Seat
    Contact
    Info
    Christopher Mirabelli Ph.DChief Executive Officer, President and Board Member
    Christopher Mirabelli Ph.D Chief Executive Officer, President and Board Member

    Anexon Board Members (1)

    NameRepresentingRoleSinceContact
    Info
    Steven Van NurdenSelfBoard Member000 0000
    Steven Van Nurden Board Member Self
    Request full access to PitchBook